{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:10:10Z","timestamp":1749183010320,"version":"3.41.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>About 85,000 melanomas are diagnosed every year in the United States, but only about 3.2% are diagnosed without a primary site. This article describes a patient who presented with two rapidly growing axillary masses and was found to have metastatic melanoma of the lymph nodes with no known primary site. Melanoma of unknown primary (MUP) site is staged either III or IV level. Management is determined in the same manner as stage-matched melanoma of known primary site.<\/jats:p>","DOI":"10.1097\/01.jaa.0000923580.98644.55","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T17:01:27Z","timestamp":1687885287000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A patient with rapidly growing axillary masses"],"prefix":"10.1097","volume":"36","author":[{"given":"Jurga","family":"Marshall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirela","family":"Bruza-Augatis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch1","article-title":"Epidemiology of melanoma","author":"Matthews","year":"2017","journal-title":"Cutaneous Melanoma: Etiology and Therapy"},{"key":"R2-20250605","doi-asserted-by":"crossref","DOI":"10.15586\/codon.noncutaneousmelanoma.2018.ch7","article-title":"Melanoma of unknown primary","author":"Scott","year":"2018","journal-title":"Noncutaneous Melanoma"},{"issue":"2","key":"R3-20250605","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.04.007","article-title":"Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature","volume":"78","author":"Kamposioras","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"R4-20250605","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07357900701781762","article-title":"Extracutaneous malignant melanomas","volume":"26","author":"Hussein","year":"2008","journal-title":"Cancer Invest"},{"issue":"110","key":"R5-20250605","first-page":"231","article-title":"Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor","volume":"20","author":"Heppt","year":"2015","journal-title":"Discov Med"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u2014update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Cancer"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.critrevonc.2020.103208","article-title":"Melanoma of unknown primary: new perspectives for an old story","volume":"158","author":"Boussios","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"R8-20250605","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1008201931959","article-title":"Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study","volume":"9","author":"Vijuk","year":"1998","journal-title":"Ann Oncol"},{"issue":"9","key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/(SICI)1097-0142(19970501)79:9<1816::AID-CNCR26>3.0.CO;2-#","article-title":"Melanoma of unknown primary site: presentation, treatment, and prognosis\u2014a single institution study. University of Pennsylvania Pigmented Lesion Study Group","volume":"79","author":"Anbari","year":"1997","journal-title":"Cancer"},{"issue":"1","key":"R10-20250605","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2014.09.029","article-title":"Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies","volume":"72","author":"Bae","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"R11-20250605","doi-asserted-by":"crossref","first-page":"e66953","DOI":"10.1371\/journal.pone.0066953","article-title":"Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour","volume":"8","author":"Weide","year":"2013","journal-title":"PLoS ONE"},{"issue":"7","key":"R12-20250605","first-page":"306","article-title":"Management decisions for nodal metastasis from an unknown primary melanoma","volume":"7","author":"Lee","year":"2008","journal-title":"Am J Hematol Oncol"},{"author":"Swetter","key":"R13-20250605","article-title":"NCCN: Clinical Practice Guidelines in Oncology, Melanoma: Cutaneous"},{"issue":"23","key":"R14-20250605","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"R15-20250605","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"issue":"20","key":"R16-20250605","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"R17-20250605","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000923580.98644.55","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:02:32Z","timestamp":1749153752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000923580.98644.55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000923580.98644.55","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}